Developed Countries

The recent rebound is not a harbinger of a prolonged recovery in risk assets. The many potential negatives will keep volatility high and trigger further occasional selloffs.

Return on equity (ROE) has clearly peaked for the cycle (top panel). In fact, S&P 500 ROE topped out in 1999 and has shown a pattern of descending cyclical tops since then. Employing the DuPont framework, ROE is declining because of falling asset turnover and decreasing margins, despite rising leverage. In more detail, the structural decline in asset turnover (second panel) reflects deteriorating corporate efficiency - owing to weak productivity growth - since asset turnover measures the amount of revenue generated per dollar of assets. Profit margins have clearly peaked for the cycle (third panel), and downward pressures are intensifying. In a deflationary world rife with excess capacity, pricing power is deteriorating for the majority of U.S. companies, at a time when wages continue to rise, albeit slowly. Importantly, ROE is declining despite rising financial leverage. It made sense for companies to leverage up over the past few years given the low after-tax, real cost of debt. Unfortunately, most of this debt was used for short-term purposes such as stock buybacks and M&A, rather than long-term investment to improve productivity and ROE. Moreover, the capacity of rising debt levels to increase ROE has reached its limit. Bottom Line: All three trends raise the risk profile of U.S. equities. Please see yesterday's Special Report for additional details.

The Treasury market is now discounting too slow a pace of Fed tightening, while junk spreads are discounting too rapid an increase in the default rate. This week we examine the risk/reward proposition of temporarily leaning against some prevailing long-run macro trends.

Inflation expectations in the Developed Markets have been adjusting down to the lower trend of actual inflation, although the bulk of this adjustment now appears complete.

Special Report

In this Special Report for the U.S. "Super Tuesday" primary elections, we offer a short primer on what you really need to know about the nomination process. We explain why Clinton's nearly inevitable victory will still take time, and why a "brokered" Republican convention in July is not enough to stop the Trump juggernaut. This sets the stage for our coverage of what promises to be a wild election with important consequences for American productivity, economic growth, and political risk.

For the month of February, the model underperformed both global and U.S. equities. For March, the model has modestly pared back its equity risk exposure, shifting the allocation into bonds. While Europe remains the largest equity overweight, EM and Canada also received some allocation. The U.S. and New Zealand were slightly downgraded. In the fixed-income space, the model is sticking with Italy and Spain.

Special Report

The risk to ROE remains to the downside, which suggests that valuation multiples have peaked for the cycle. Beyond a potentially violent near-term counter-trend bounce, valuation multiples will remain under pressure.

Special Report

The risk to ROE remains to the downside, which suggests that valuation multiples have peaked for the cycle. Beyond a potentially violent near-term counter-trend bounce, valuation multiples will remain under pressure.

Special Report

We are introducing a new set of fair value models for currencies. On a cyclical basis, the dollar is expensive. However, this is not enough of a reason to expect an imminent fall in the greenback. The yen is extremely cheap, and its fair value is rising on the back of a positive terms-of-trade shock. The yuan is fairly valued. Most commodity currencies are not yet cheap.

The retail drug store industry is enjoying a twin boost from both bullish cyclical and secular forces. The latter is reflected in the long-term advance in personal outlays at pharmacies, which likely reflects increased drug demand as a consequence of an aging population. From a cyclical perspective, the surge in health care sector hiring activity reflects increased health coverage and rising patient volumes. That is a boon for drug demand, and is consistent with rising store traffic. As a result, pharmacies should be able to continue lifting selling prices at a rapid clip, despite deep deflation in the overall corporate sector. The upshot is ongoing productivity gains, as measured by sales/employee, should support robust earnings performance and a relative valuation re-rating. Stay with a high-conviction overweight. The ticker symbols for the stocks in this index are: WBA, CVS.